<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03147963</url>
  </required_header>
  <id_info>
    <org_study_id>ZCHBC0011</org_study_id>
    <nct_id>NCT03147963</nct_id>
  </id_info>
  <brief_title>Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer</brief_title>
  <official_title>A Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety of a Single Agent Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer to a 3-weeks Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety of a Single Agent
      Docetaxel 2-Weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer to a
      3-Weeks Regimen
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Docetaxel 2-Weeks Regimen:Docetaxel 50mg/m2 Docetaxel 3-Weeks Regimen:Docetaxel 75mg/m2
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2015</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>patients was divided 1:1 into docetaxel 2-weeks regimen group and docetaxel 3-weeks regimen group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>From date of enrolling until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 5 years</time_frame>
    <description>Progression-free survival (PFS) is defined as the time elapsed between enrolling and tumor progression or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>From date of enrolling until the date of death from any cause, assessed up to 5 years</time_frame>
    <description>The time elapsed between enrolling and death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate(CBR)</measure>
    <time_frame>From date of enrolling until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 5 years</time_frame>
    <description>The response is CR+PR+SD ≥ 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life（QOL）</measure>
    <time_frame>From date of enrolling until the date of first documented progression or date of death from any cause, whichever came first，assessed up to 5 years</time_frame>
    <description>Score change from enrolling to progression disease or death according EORTC QLQ-C30.The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Grade 3/4 adverse events</measure>
    <time_frame>From date of enrolling until the date of 1 month of stop treatment, assessed up to 5 years</time_frame>
    <description>Number of participants with Grade 3/4 adverse events of the two groups was assessed in accordance with the common terminology criteria (NCI CTC AE) version 4.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel 2-Weeks regimen group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel injection 50mg/m2,iv,d1,every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel 3-Weeks regimen group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel injection 75mg/m2,iv,d1,every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel will be given until progression or patient intolerance</description>
    <arm_group_label>Docetaxel 2-Weeks regimen group</arm_group_label>
    <arm_group_label>Docetaxel 3-Weeks regimen group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  The age is Above 18 years of age, &lt;70 years old

          -  The diagnosis of breast cancer was confirmed by cytological examination or
             pathological examination. HER2-negative

          -  Clinical stage was metastatic breast cancer or locally advanced breast cancer.

          -  Must have at least one measurable lesion, according to RECISTv1.1.

          -  Eastern Cooperative Oncology Group performance status (ECOG PS)=0~2

          -  Docetaxel or paclitaxel can been used in initial treatment or in the past for locally
             advanced, recurrent or metastatic lesions,if used must been proved effective, and
             recent progress over 6 months.

          -  The basic function of normal bone marrow

          -  Functions of liver and kidney is normal

          -  Expectation of life is more than 3 months

          -  Agreed to take contraceptive measures during treatment

        Exclusion Criteria:

          -  The patient had a history of allergy to taxanes or their components.

          -  Recent progress of taxanes in 6 months.

          -  In the elution period of other chemotherapy regimens.

          -  Severe coagulopathy.

          -  HER2 positive breast cancer

          -  Previous toxicity was not recovered to 0-1 degrees

          -  Central nervous system metastasis had not Controlled yet

          -  Pregnancy or lactation

          -  There are uncontrolled infection, myocardial infarction, thrombosis, etc.

          -  There are uncontrolled chronic diseases such as diabetes, hypertension, peptic ulcer,
             chronic hepatitis, mental disease;

          -  HIV infection

          -  Patients with other malignant tumor history, except the healed skin basal cell
             carcinoma and carcinoma of uterine cervix;

          -  Researchers believe that is not suitable for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojia WANG, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaojia WANG, MD,PHD</last_name>
    <phone>8613906500190</phone>
    <email>wxiaojia0803@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ping HUANG, MD</last_name>
    <phone>8613685766632</phone>
    <email>zlyyhp@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojia WANG, MD,PhD</last_name>
      <phone>+86 13906500190</phone>
      <email>wxiaojia0803@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Ping HUANG, MD</last_name>
      <phone>+86 13685766632</phone>
      <email>zlyyhp@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiaojia WANG, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P; TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003 Mar 15;21(6):968-75. Erratum in: J Clin Oncol. 2003 May 15;21(10):2048.</citation>
    <PMID>12637459</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>May 7, 2017</last_update_submitted>
  <last_update_submitted_qc>May 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Huang Ping</investigator_full_name>
    <investigator_title>attending doctor</investigator_title>
  </responsible_party>
  <keyword>therapy</keyword>
  <keyword>breast cancer</keyword>
  <keyword>docetaxel</keyword>
  <keyword>metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

